T-Therapeutics Secures Additional Funding for Innovative Therapeutics
In a significant financial boost, the British biotechnology firm, T-Therapeutics, has successfully completed an extension of its Series A financing, raising an impressive €27.5 million (approximately $32 million). This brings the total funding acquired in this round to €78.2 million ($91 million) after the initial €50.7 million was raised earlier. New backers, including Tencent and BGF, joined the ranks of existing investors such as Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, and the University of Cambridge Venture Fund.
The CEO of T-Therapeutics, Theodora Harold, remarked on the successful fundraising effort, expressing gratitude towards both new and existing investors for their confidence in the company’s potential. She emphasized that the additional capital reinforces the company’s commitment to developing transformative medicines aimed at addressing the fundamental causes of diseases.
Positioning T-Therapeutics in the European Immuno-Oncology Landscape
This recent funding round places T-Therapeutics firmly within the broader context of European immunotherapy advancements in 2025. Notable developments in the region include Adcytherix in France, which raised €105 million to enhance its antibody-drug conjugate pipeline, and Adaptam Therapeutics in Spain, securing €3 million for its therapies targeting immunosuppressive myeloid cells. Such investments underscore a continued interest among investors in the European immuno-oncology sector, with a collective total of approximately €108 million flowing into this area this year.
Managing Partner of Sofinnova Partners, Graziano Seghezzi, pointed out that the additional funding will enable T-Therapeutics to explore T cell subset depletion, an exciting frontier in immunology, while advancing its oncology programs. He expressed confidence that T-Therapeutics is now well-positioned to tackle both oncology and autoimmune diseases, which present critical unmet medical needs.
Innovative Approaches and Future Directions
Founded in 2022, T-Therapeutics emerged from the University of Cambridge with a focus on exploiting T cell biology to develop effective treatments for cancer and autoimmune disorders. The company’s unique T cell receptor (TCR) platform, named OpTiMus, is designed to generate a diverse range of high-specificity, fully human TCRs, allowing access to previously challenging intracellular targets. Additionally, the company has developed proprietary CD3 T cell engagers (TCEs) engineered for enhanced potency and safety, which are combined with OpTiMus-derived TCRs to create groundbreaking bispecific drug candidates.
The funds raised will be used to propel T-Therapeutics’ pipeline of innovative TCR-CD3 bispecifics through clinical development, particularly focusing on new therapeutic strategies, including the targeted depletion of pathogenic immune cells in autoimmune conditions. Their leading oncology candidate is aimed at a pan-tumor driver target, applicable across various solid tumors, while their immunology program seeks to achieve precision immune reset through selective immune cell depletion.
Partner at BGF, Luke Rajah, highlighted the exceptional track record of T-Therapeutics’ leadership team in drug discovery and the transition of scientific insights into effective treatments. He expressed pride in supporting a company that stands to unlock previously inaccessible targets with its innovative bispecific therapies, aiming to bring meaningful solutions to patients in need.
As T-Therapeutics continues to advance its research and development efforts, the company remains committed to addressing significant health challenges in oncology and autoimmune diseases, paving the way for potential breakthroughs in treatment options.
Related
